ANALYGENCE awarded a prime contract on by the Food and Drug Administration (FDA)

ANALYGENCE was awarded a prime contract on September 23, 2019 by the Food and Drug Administration (FDA) in support of the Center for Biologics Evaluation and Research’s (CBER’s) Biologics Effectiveness and Safety (BEST) Initiative. For this effort, ANALYGENCE is developing a site to host web content that will be made publicly available in order to allow the BEST team to communicate effectively with healthcare professionals and with the general public about vaccines, blood and blood products, tissues and advanced therapeutics, and other topics.